BIO-FD&C Co.,Ltd. (KOSDAQ:251120)
16,070
+150 (0.94%)
At close: Jan 28, 2026
BIO-FD&C Revenue
BIO-FD&C had revenue of 5.07B KRW in the quarter ending September 30, 2025, with 40.99% growth. This brings the company's revenue in the last twelve months to 18.82B, up 17.12% year-over-year. In the year 2024, BIO-FD&C had annual revenue of 16.07B with 3.04% growth.
Revenue (ttm)
18.82B
Revenue Growth
+17.12%
P/S Ratio
7.54
Revenue / Employee
n/a
Employees
n/a
Market Cap
141.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.07B | 474.34M | 3.04% |
| Dec 31, 2023 | 15.59B | -263.23M | -1.66% |
| Dec 31, 2022 | 15.86B | 3.88B | 32.43% |
| Dec 31, 2021 | 11.97B | 3.33B | 38.57% |
| Dec 31, 2020 | 8.64B | 163.27M | 1.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 132.76B |
| KoBioLabs | 71.83B |
| CORESTEMCHEMON | 20.13B |
| QuadMedicine | 13.11B |
| TiumBio | 9.32B |
| Bio Solution | 8.27B |
| TegoScience | 6.15B |
| NovMetaPharma | 1.30B |